Antibiyotikler, zararlı bakteriyel patojenleri yok ederek ya da inaktif hale getirerek etki gösteren ajanlardır. Günümüzde antibiyotiklerin tasarlanmasında genom bilimi, proteom bilimi, metabolom bilimi ve interaktom bilimi gibi "om" bilimlerinden (ya da "omik" bilimlerden) büyük ölçüde yararlanılmaktadır. Bu derlemede bu bilimlerin basitten karmaşığa giden farklı yönle-ri tartışılmaktadır. Piramidin en altındaki basit dizi analizinden üst kısmındaki karmaşık -yapısal, fonksiyonel ve interaksiyonelanalizlerin tümü, omik bilimlerin kapsamına girmektedir. Dizi karşılaştırması, bakterilerdeki ilaç direncine ilişkin yeni bilgiler sunabilmesi nedeniyle, yeni antibiyotik geliştirilmesinde son derece önemlidir. Öte yandan, konak proteininin dizilenmesi, etkili antibiyotiklerin sentetik olarak üretilmesine olanak tanıyabilir. Günümüzde bilgisayar destekli bağlanma teknikleri kullanıldığı yapıya dayalı molekül tasarımı, ilaç tasarım süreçlerinde geniş ölçüde kabul gören rutin bir işlem haline gelmiştir. Ayrıca, mikroçip ekspresyonu, protein-protein etkileşimli essey yöntemle-riyle elde edilen yeni ve yüksek verimli veriler, çok daha fazla ilaç hedefinin keşfi için yeni ufuklar açmaktadır. Konak-patojen etkileşimini sistemler düzeyinde anlamak için gösterilen yoğun çabalar, tüberküloza ve benzer pek çok karmaşık hastalığa kar-şı etkili antibiyotiklerin tasarlanması sürecini hızlandırmıştır. Özetle, bu derlemede omik bilimlerin, yeni antibiyotiklerin keşfi alanındaki paradigmayı, gittikçe artan bir biçimde nasıl değiş-tirdiğine ilişkin çeşitli örnekler sunulmaktadır. Omik yaklaşım, önümüzdeki dönemde bu süreci daha da hızlandıracak ve antibiyotiklerin maliyetini daha da düşürecektir. 
Introduction
Antibacterials, alternatively known as antibiotics, fall into the broad group of small molecules that act against bacteria by various mechanisms (1) (2) (3) (4) . A key difference between antibiotics and vaccine is that a vaccine may work to bolster immune responses against pathogenic infection and essentially do not act directly on the microbe itself whereas in contrast antibacterials works against the pathogens directly to kill or inactivate them (5) .
Today, antibacterial designing has become greatly assisted by omics sciences. Omics sciences include a wide spectrum of themes: genomics, proteomics, metabolomics and interactomics. Genomics deals with gene information and makes sense of it (6) . Proteomics involves the study protein structure and function (7) . Metabolomics investigates integrated information about metabolic pathways (8) whereas interactomics refers to the study of all the possible interactions, such as DNA-protein, protein-protein, proteinsmall molecule interactions within living cells (9) (10) (11) . Omics sciences are helpful in elucidating the sequence, structure and functional information about both the pathogen and host genes and proteins (12) (13) (14) .
Complete genome sequences of bacterial organisms have had a revolutionary effect on the process of designing new antibiotics. The completion of nearly 30 bacterial wholegenome sequences and ongoing sequencing projects of over 100 microbial organisms will allow researchers to probe novel therapeutic targets (15) . The search for new antibiotics can be extensively assisted by computational methods such as homology-based analyses, structural genomics, motif analyses, protein-protein interactions, molecular docking and experimental functional genomics (15) . However the greatest obstacle of computational assays is massive volume of data from the genome sequences and making sense of it. The sequence of microbial pathogens catalogs every gene product that would be relevant for the host-parasite interaction and potential antibiotic drug target (16, 17) . Therefore, scientists interested in discovering antibiotics must extract useful information from genomes through comparative, functional, or structural genomics in order to simplify drug target selection.
Whole Genome Sequencing: A Gateway to Designing Better Drug

Sequence Comparison
Useful antibiotic development and the bacterial whole-genome sequences go hand in hand. However, the concurrence of the two is even more significant as increasingly resistance of commonly used antibiotics have been developed in bacteria. A growing prevalence of infections, and the emergence of new pathogenic organisms is challenging current antibiotics pool (18) . When antibiotics synthesized afresh resembles that of the ones used earlier to ones already rendered ineffective, resistance is more likely to happen (19) . This poses a great concern for the clinicians and world health in large, as resistant-to-antibiotic bacteria can trigger a massive global epidemic. Ideally, new antimicrobial compounds should have novel mechanisms of action.
Phylogenetic trees are an essential tool that are used to identify recognized sequence homology pattern which can be very useful to identify essential genes for the pathogens (20) . One can also design a antibacterial that works against an entire phylogenetic group in order to target all of the organisms with a broad-spectrum antibiotic. Thus the concept of universal antibacterials has flourished using sequence comparison tools.
Well before whole genome sequencing for bacteria became popular, sequencing of many apparently important genes was carried out. However, with DNA sequencing becoming a household scientific exercise, sequence comparison has been an exciting technique that took the world by storm. Sequence comparison has been an exciting new technology to compare sensitive and resistant strains of the bacteria. In a widely cited paper authored by Fournier et al. (21) a similar study was carried out for a multidrug resistant strain. Similar studies have been carried out for Streptococcus, Staphylococcus and Deinococcus (22) (23) (24) (25) (26) . Several computational tools and online databases have also gained prominence over the years (27) . Some of the computational databases are enlisted in Table 1 .
Sequence Characterization
Sequence characterization is another key theme associated with designing functioning antibiotic target. Often a motif or a profile is found in the genomic or peptide sequence of the antibacterial targets (73) . Sequence characterization is also of great importance for analyzing actions of the peptide antibiotics (74) . Thus comparison between resistant and sensitive strain requires a detail characterization of the protein or genomic sequence of the both target molecules and peptide antibiotics (75, 76) .
Commonly used antibiotic drugs target series-specific genes, unique enzymes and membrane transporters (77) . The mechanism of action how antibiotics mediate its response is diverse; some antibiotics prevent protein synthesis and nucleic acid replication, some inhibit cell wall or membrane synthesis, some rather prevents membrane transport (78) . In this regard, all the bacteria have a special set of proteins that are responsible for either causing virulence or taking hold of host machinery. Identifying those genes are of supreme importance and hence sequence characterization for bacteria for which no sequence information is deposited of yet, is the only option in that case.
To begin with, in a novel bacteria sequence characterization flow chart, scientists start characterizing all the open reading frames of bacterial sequences and make a map of all genes and gene products (79, 80) . Afterwards, they must pick out the genes that are essential to cell survival or growth, which are most effective as antibiotic targets. Often the line of action to detect this genes is to go for a random mutagenesis and subsequent phenotyping of the bacteria (16) . However, the job today has become a lot easier as representative genome sequences from almost all the pathologically and economically important bacteria has already been done. And with this being done even the primary sequence comparison programs, like BLAST or PSI-BLAST, can determine gene functions by sequence homology.
Motif analysis is another strategy to identify potential antibiotic targets among genes with unknown functions. Many databases, including PROSITE, InterPro, BLOCKS, Pfam etc., can search for motifs in a sequence (16, (81) (82) (83) (84) (85) (86) (87) (88) (89) (90) (91) (92) (93) . The motifs may show the approximate biochemical function of the gene.
Gene fusion is another computational method to infer protein interactions from genome sequences. Proteins that interact with each other tend to have homologs in other organisms. This evolutionary calling-of-function method often gives out functional information for target proteins (16) .
Function Based Techniques Help Selecting Soft Targets for Designing Antibiotic against It
Assigning functions to the genes is one of the major steps involved in designing soft targets in bacteria for which drug can be designed. Identifying the genes that are essential for proper functioning of the bacteria is thus also important. Many online databases contain these information and thus can be tremendously useful for antibacterial designing (94, 95) .
Microarray or Fuzzy Algorithms
There are some disadvantages associated to sequence homology based methods. About 25-40% of the genes in a bacterial genome usually do not find matches with known genes (79, 80) . Furthermore, sequence homology is based on the assumption that similar sequences will share similar functions -an assumption that does not hold true in many cases where similar sequences are structurally and functionally diverse.
Therefore, alternatives to sequence homology techniques had to be established. To predict the function of a gene, cluster analysis of the expression profile has been extensively used. Cluster analysis uses microarray technology to analyze gene expression in order to organize genes into functional groups (96) . Genes for which no annotation has been assigned can be classified into a functional group and thus can be assigned a functional annotation on the basis of microarray data instead of sequence data. Protein synthesis patterns are also useful to analyze the antimicrobial effect certain drugs would have on particular necessary or important proteins (97) .
Systems Biology
Using systems biology to design drugs have been a popular approach in the post genomic era (98) . Systems biology considers genes and proteins to be integrated to each other and hence takes up an integrated approach for drug designing (99,100). Protein-protein interaction (PPI) and gene regulatory networks (GRN) are one of the most recurrent themes of systems biology in designing drugs. PPI exposes novel information about whole proteome interaction status (101, 102) . A common strategy of the systems biology investigators has been looking for most densely interconnected protein, known as hub proteins, in the systems map; hub proteins often make a good antibiotic target (103) (104) (105) . Similarly DNA-protein interaction and GRN has been an important tool to understand host pathogen interaction and host cellular mechanism (106,107). Systems biology has been applied assaying drugs against pathogens with complex life cycle. Detecting a universal drug against these pathogens have been difficult as they drug target proteins are often poorly understood. However, today systems approach has been applied successfully to design antibacterials against tuberculosis and gastric ulcer (108) (109) (110) (111) .
Structure Based Techniques Assists Designing Molecular Medicine against Pathogens
Although assigning gene function by cluster analyses is quite useful as described in the earlier section, they are also subject to significant level of discrepancies as well. Some proteins have multiple functions and likewise, some functions require multiple proteins (8) .
Therefore, structural genomics has been used as a better method of drug target selection. Function is more directly related to its structure than its sequence (96) . Now even considerable number of protein 3D structures in the native tertiary form has also been deposited in structure databases. That makes possible the task of comparing different protein structures and annotating functions accordingly. Some such protein structure databases are RCSB Protein Data Bank (PDB), PDBsum, ModBase, Proteopedia, 3D Complex, SCOP etc. (112) (113) (114) (115) (116) .
Another property of the drug target should be nonredundancy that is the target should be structurally different or nonexistent in humans. Checking for structural homology against a human genome protein structure database would determine whether the antibiotic against that drug target would also interfere with any human functions.
Another key advantage of structure based medicines is that the action of the drug is very predictable in nature. Because the drug-protein interaction involves a complementary fit to each other and not any coexpression information, they are remarkably specific in their mode of action most of the times (117) (118) (119) (120) (121) . These very properties have made structural methods an ideal choice for selection of drug targets. However, structural databases are not complete since quality protein-crystals are difficult to form and hinders x-ray crystallography (122) . However, nuclear magnetic resonance can determine 3D structure determination. Also, computational modeling is approaching accurate functional predictions based on alignment of amino acid sequences (123) .
The use of computational methods and expression profiling all point to the need for a non-redundant, complete database of structural and functional annotation of the proteins from known pathogenic bacteria genomes and the human genome, once it is completed. The organization, accuracy, and easy accessibility of such databases are crucial in the hunt for novel antibiotics. Perhaps a program can be specifically designed to highlight antibiotic drug targets in query sequences. This program would scan structural databases and other bacterial genomes for homology and similar folds. The program could be complemented by a central, tailored database that reorganizes data for the most efficient search of novel antibiotic targets, for example, each protein or gene that is essential to certain bacterial species. For example, the database could include the protein's phylogenetic group, 3D structure, proteins of similar structural homology, and whether any similar protein exists in humans. It could also use foreign keys to connect to other databases that catalogue which known antibiotics and inhibitors are used against similar targets.
Conclusion
Summarizing, the computational methods and omics sciences has become an integral part of designing novel antibacterials. Therefore, along with structure function annotation to ensure rapid and effective communication of the in vitro results has become an absolute essential in this regard. In silico experimentations have also added to the data wealth and thus an efficient data management is also the call of the hour.
One should not get carried away by the whole-genome sequence data available; there are still many hurdles to overcome. One of the major problems is the localization of the drug target and an efficient drug delivery that can hardly be analyzed by omics tools (124) . Therefore requirement of drug response databases -databases that deposit pharmacokinetic and pharmacodynamic data-are also gaining prominence. Despite limitations there are some databanks growing for small molecules and their properties (125) . Approval and strict patent laws is another administrative hurdle that makes commercialized antibacterials something extremely hard to materialize. Lastly but more importantly, an indiscriminate use of antibiotics is, in an unprecedented speed, making more and more bacterial species resistant and this is putting unmanageable pressure to the demand of antibiotic. Scaling up antibacterial production has improved to a great extent over the last few decades, yet the supply of antibacterials hardly catches up to the demand (126) . All these pose severe challenges for designing antimicrobials. However, it is to be noted that never before technologies, computer aided tools, huge workforce and human intelligence worked in so unified nature. Hence, it would not be an overstatement to say that the days today for novel antibacterials designing are brighter than it has ever been before.
